Cite
HARVARD Citation
Hansen, A. et al. (n.d.). 357 Toxicity remains the key determinant of recommended phase II dose (RP2D) of anticancer agents despite increasing use of non-toxicity endpoints. European journal of cancer. pp. S73-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Hansen, A. et al. (n.d.). 357 Toxicity remains the key determinant of recommended phase II dose (RP2D) of anticancer agents despite increasing use of non-toxicity endpoints. European journal of cancer. pp. S73-. [Online].